Trial Profile
Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Binge-eating disorder
- Focus Therapeutic Use
- Acronyms BELIEVE
- 04 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 14 May 2019 Planned End Date changed from 20 Apr 2020 to 1 Oct 2019.
- 14 May 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Sep 2019.